机构:[1]Department of Hepatobiliary Surgery and Liver Transplantation, Liver Cancer Institute, Zhongshan Hospital, Fudan University, Shanghai, People's Republic of China.[2]Hepatic Surgery Center, Tongji Hospital, Tongji Medical College of Tongji Medical College, Huazhong University of Science & Technology, Wuhan, People's Republic of China.华中科技大学同济医学院附属同济医院[3]Department of Liver Surgery, West China Hospital, Sichuan University, Chengdu, People's Republic of China.四川大学华西医院[4]Department of Hepatobiliary Surgery, the First Affiliated Hospital of USTC, Division of Life Sciences and Medicine, University of Science and Technology of China, Hefei, People's Republic of China.
第一作者机构:[1]Department of Hepatobiliary Surgery and Liver Transplantation, Liver Cancer Institute, Zhongshan Hospital, Fudan University, Shanghai, People's Republic of China.
共同第一作者:
通讯作者:
推荐引用方式(GB/T 7714):
Sun Hui-Chuan,Huang Zhi-Yong,Wen Tianfu,et al.Adjuvant Lenvatinib for High-Risk CNLC IIb/IIIa Hepatocellular Carcinoma After Curative Hepatectomy: A Prospective Exploratory Study[J].Journal Of Hepatocellular Carcinoma.2025,12:1043-1056.doi:10.2147/JHC.S516478.
APA:
Sun Hui-Chuan,Huang Zhi-Yong,Wen Tianfu,Liu Lianxin,Zhu Xiao-Dong...&Zhou Jian.(2025).Adjuvant Lenvatinib for High-Risk CNLC IIb/IIIa Hepatocellular Carcinoma After Curative Hepatectomy: A Prospective Exploratory Study.Journal Of Hepatocellular Carcinoma,12,
MLA:
Sun Hui-Chuan,et al."Adjuvant Lenvatinib for High-Risk CNLC IIb/IIIa Hepatocellular Carcinoma After Curative Hepatectomy: A Prospective Exploratory Study".Journal Of Hepatocellular Carcinoma 12.(2025):1043-1056